Published in Medicine and Law Weekly, April 8th, 2005
The multicenter open label phase IIb study is being conducted by Cancer Trials Australia, a consortium of four Melbourne Hospitals and three Research Institutes. Of these, the three consortium members participating in the study include Melbourne's Austin Health, Royal Melbourne Hospital and the Peter MacCallum Cancer Center.
To date, 36 of the 40 anticipated participants in the study have been enrolled and dosed. The study is designed to confirm the safety...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.